IRF
NBIX icon

IBM Retirement Fund’s Neurocrine Biosciences NBIX Stock Holding History

IBM Retirement Fund’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,629
Closed -$252K – 650
2021
Q3 		$252K Hold
2,629
– – 0.02% 630
2021
Q2 		$256K Sell
2,629
-492
-16% -$47.2K 0.02% 648
2021
Q1 		$304K Sell
3,121
-264
-8% -$27.7K 0.02% 611
2020
Q4 		$324K Buy
3,385
+396
+13% +$38.2K 0.02% 577
2020
Q3 		$287K Buy
2,989
+840
+39% +$97.2K 0.02% 533
2020
Q2 		$262K Buy
+2,149
New +$237K 0.03% 435
2017
Q1 		– Sell
-6,892
Closed -$267K – 602
2016
Q4 		$267K Sell
6,892
-1,277
-16% -$57.8K 0.01% 812
2016
Q3 		$414K Sell
8,169
-512
-6% -$25.5K 0.02% 710
2016
Q2 		$395K Buy
+8,681
New +$400K 0.01% 757

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IBM Retirement Fund's NBIX Position: Q4 2021 in Review

IBM Retirement Fund sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 2,629 shares — an estimated $252K sold.

IBM Retirement Fund first reported a position in NBIX in Q2 2016 and held it in 9 quarters. The position peaked at $414K in Q3 2016. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

  • IBM Retirement Fund reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
  • IBM Retirement Fund sold 2,629 Neurocrine Biosciences shares in Q4 2021, an estimated $252K.
  • IBM Retirement Fund first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 9 quarters.
  • IBM Retirement Fund's Neurocrine Biosciences position peaked at $414K in Q3 2016.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on IBM Retirement Fund's 13F filing for Q4 2021, filed 19 Jan 2022.